DelveInsight has launched a new report on “Giant Axonal Neuropathy – Market Insights, Epidemiology, and Market Forecast-2032”.
Some of the key facts of the Giant Axonal Neuropathy Market Report:
According to a Japanese case study by Koichihara et al. (2016), mild GAN, particularly in the early stages, can be misdiagnosed because of lack of typical hair features and incomplete or indistinct peripheral and central nervous system symptoms. This case is important since it can aid to identify atypical and milder clinical courses of GAN.
Laguna et al. (2020), in a multicenter observational retrospective study, recorded French patients with GAN mutations, and 10 patients were identified. The mean age of patients was 9.7 years (2–18), and all patients met infant developmental milestones and had a family history of consanguinity. The mean age at disease onset was 3.3 years (1–5), and patients used a wheelchair at a mean age of 16 years (14–18). Patients also showed a variety of associated findings, including curly hair (100% of cases), pes cavus (80%), ophthalmic abnormalities (30%), and scoliosis (30%). Five new GAN mutations were found, including the first synonymous mutation and a large intragenic deletion.
Key benefits of the report:
Giant Axonal Neuropathy market report covers a descriptive overview and comprehensive insight of the Giant Axonal Neuropathy Epidemiology and Giant Axonal Neuropathy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Giant Axonal Neuropathy market report provides insights into the current and emerging therapies.
Giant Axonal Neuropathy market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Giant Axonal Neuropathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Giant Axonal Neuropathy market.
Giant Axonal Neuropathy Overview
Giant axonal neuropathy (GAN) is a rare inherited genetic disorder that severely affects the peripheral as well as the central nervous system. GAN is characterized by abnormally large and dysfunctional axons called giant axons. The onset of GAN ranges from early infancy to late childhood
This neurodegenerative disorder is caused by mutations in the GAN gene located on chromosome 16 at 16q24.1 which provides instructions for making a protein called gigaxonin protein. The nonstandard gigaxonin protein causes a portion of the nerve cell called the axon to swell up with deposits of tiny threads of a protein called neurofilaments, giving the presence of giant axons. The giant axons cause degeneration and abnormal functioning of the peripheral nervous system. This condition is inherited in an autosomal recessive pattern, which means both copies of the gene present in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they usually do not show signs and symptoms of the condition. As per some studies, since the first GAN report in 1972, more than 50 GAN gene mutations have been identified.
Giant Axonal Neuropathy Market
The dynamics of the Giant Axonal Neuropathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Taysha Gene Therapies and others during the study period 2019-2032.
Learn more by requesting for sample @ Giant Axonal Neuropathy Market Landscape
Giant Axonal Neuropathy Pipeline Therapies and Key Companies
TSHA-120: Taysha Gene Therapies
Giant Axonal Neuropathy Market Drivers
Active participation of the different organization in increased R&D
Regulatory incentives such as market exclusivity for orphan designated drugs
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Giant Axonal Neuropathy Patient Share (%) Overview at a Glance
5. Giant Axonal Neuropathy Market Overview at a Glance
6. Giant Axonal Neuropathy Disease Background and Overview
7. Giant Axonal Neuropathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Giant Axonal Neuropathy
9. Giant Axonal Neuropathy Current Treatment and Medical Practices
10. Unmet Needs
11. Giant Axonal Neuropathy Emerging Therapies
12. Giant Axonal Neuropathy Market Outlook
13. Country-Wise Giant Axonal Neuropathy Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Giant Axonal Neuropathy Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
Click here to read more about Giant Axonal Neuropathy Market Outlook 2032.
Giant Axonal Neuropathy Pipeline
Giant Axonal Neuropathy Epidemiology
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States